Latest:
Dr Zonder on the Outcomes of the PERSEUS Trial in Multiple Myeloma
Jeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jeffrey Zweig, MD
Latest:
The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?
With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.
Jena D. French, PhD
Latest:
Jena French on Combinations With Immunotherapy in Thyroid Cancer
Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib as treatment for patients with thyroid cancer.
Jennifer Bellon, MD
Latest:
Dr. Bellon on Ongoing Trials in Omitting Radiation in Breast Cancer Treatment
Jennifer Bellon, MD, radiation oncologist, Dana-Farber Cancer Institute, discusses some of the current ongoing trials looking at omitting radiation when it comes to the treatment of patients with breast cancer.
Jennifer Carlisle, MD
Latest:
Dr. Carlisle on Chemoimmunotherapy as Frontline Standard in Squamous NSCLC
Jennifer Carlisle, MD, assistant professor, Winship Cancer Institute of Emory University, discusses how the use of chemoimmunotherapy has become the standard of care in the frontline treatment of patients with squamous non–small cell lung cancer.
Jennifer Chan, MD, MPH
Latest:
Dr. Chan on Trial of Cabozantinib in Neuroendocrine Tumors
Jennifer Chan, MD, MPH, senior physician, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses a trial of cabozantinib (Cabometyx) in neuroendocrine tumors (NETs).
Jennifer Kelly, MD, PhD
Latest:
Lessons From the Other Side of the Bed: Physician Perspectives as a Cancer Patient
Oncologist Jennifer Kelly, MD, PhD, shares her personal experiences as a stomach cancer patient, recognizes the barriers between cancer care providers and patients, and suggests ways of improving these interactions.
Jennifer Kelly Shepphird, PhD
Latest:
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration
Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Jennifer L. Logan, MD, MPH
Latest:
Strategies for Lung Cancer Screening Implementation: Program Structure and Panel Profiles
The structure of lung cancer screening programs in the United States vary by resource availability, provider expertise, type of institution, and interests of the organization. Often these programs are developed through the reorganization of preexisting multidisciplinary models that have been providing services related to lung cancer.